Climb Bio, Inc. 8K

Climb Bio used a Form 8-K exhibit to present encouraging initial Phase 1 data for its anti-APRIL antibody CLYM116, supporting an every-12-week regimen, detailing the ongoing Phase 2 IgA nephropathy program, and signaling plans for Phase 3 and commercialization subject to future results and regulatory input.

Climb Bio furnished an investor presentation as Exhibit 99.2 to its Form 8‑K highlighting initial topline Phase 1 healthy-volunteer results for its anti-APRIL antibody CLYM116, which showed an approximately 29-day half-life, near-complete and durable suppression of free APRIL and substantial reductions in IgA, Gd-IgA1, and IgM with a favorable safety profile and no serious adverse events or hypogammaglobulinemia. The company reported that these pharmacokinetic and pharmacodynamic data support a convenient every-12-week subcutaneous dosing regimen (800 mg loading dose followed by 400 mg Q12W), that a high-concentration formulation and pre-filled syringe device are complete and compatible with an autoinjector, and that its NAVIGATE-2 Phase 2 trial in IgA nephropathy is actively enrolling with initial data expected in the first half of 2027. The presentation emphasizes the sizable commercial opportunity in IgA nephropathy, positions CLYM116 as a potential best-in-class next-generation anti-APRIL therapy versus first-generation competitors, and outlines a development path targeting Phase 3 initiation in 2027 subject to regulatory feedback, while cautioning that these plans and expectations are forward-looking and subject to regulatory, clinical, competitive, and financing risks.

Filing Facts

CIK

1768446

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-381060

Alert Tier

6